BibTeX
CSL-JSON
MLA
Harvard
A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine
release_xouv2l76drdlfigwtgy6mklxey
by
Laura Q. Chow, Rafael Santana-Davila, Austin Pantel, Mara Roth, Leslie N. Anderson, Alan Failor, Robert Doot, David Mankoff
Archived Files and Locations
application/pdf 3.8 MB
file_znbqi7cakjhyxckrw6fcnaz7je
|
web.archive.org (webarchive) journals.plos.org (publisher) |
application/pdf 1.7 MB
file_7vtvyz6c3jbmlpcezpgwhsakqy
|
web.archive.org (webarchive) pdfs.semanticscholar.org (aggregator) |
Read Archived PDF
Preserved and Accessible
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
access all versions, variants, and formats of this works (eg, pre-prints)
Cite This
Lookup Links
oaDOI/unpaywall (OA fulltext)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar